33996-30-4

Basic information

• Product Name: H-HYP-OET HCL
• Synonyms: Hydroxyproline ethyl ester hydrochloride;(2S,4R)-Ethyl 4-hydroxypyrrolidine-2-carboxylate hydrochloride;(2S,3R)-Ethyl 4-hydroxypyrrolidine-2-carboxylate hydrochloride;L-4-trans-Hydroxyproline ethyl ester hydrochloride≥ 99% (HPLC);4-trans-Hydroxy-L-proline ethyl ester hydrochloride;L-HYDROXYPROLINE ETHYL ESTER HYDROCHLORIDE;L-4-HYDROXY-L-PROLINE ETHYL ESTER HYDROCHLORIDE;L-4-HYDROXYPROLINE ETHYL ESTER HYDROCHLORIDE
• CAS NO: 33996-30-4
• Molecular Formula: C₇H₁₃NO₃*ClH
• Molecular Weight: 195.64
• EINECS: 251-779-0
• Mol File: 33996-30-4.mol
• Article Data: 22

Chemical Properties

• Melting Point: 150-153℃
• Boiling Point: 297.2 °C at 760 mmHg
• Flash Point: 133.5 °C
• Appearance: White/Powder
• Vapor Pressure: 0.00014mmHg at 25°C
• Storage Temp.: Store at 0-5°C
• CAS DataBase Reference: H-HYP-OET HCL(CAS DataBase Reference)
• NIST Chemistry Reference: H-HYP-OET HCL(33996-30-4)
• EPA Substance Registry System: H-HYP-OET HCL(33996-30-4)

Safety Data

• Hazardous Substances Data: 33996-30-4(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Uses

H-Hyp-OEt HCl

InChI:InChI=1/C7H13NO3.ClH/c1-2-11-7(10)6-3-5(9)4-8-6;/h5-6,8-9H,2-4H2,1H3;1H/t5?,6-;/m0./s1

Upstream product

• 64-17-5 ethanol 
• 51-35-4 4R-4-hydroxyproline 

Downstream Products

• 37813-30-2 (2S,4R)-4-hydroxyproline-1,2-dicarboxylic acid 1-tert-butyl 2-ethyl ester 
• 121758-41-6 N-<4-Methyl-3-(benzyloxy)-2-nitrobenzoyl>hydroxyproline ethyl ester 
• 103654-87-1 N--N'-<(2,2,2-trichloroethoxy)carbonyl>-L-alanyl>-L-4-hydroxyproline ethyl ester 
• 154342-88-8 (2S,4R)-ethyl N¹-benzyl-4-hydroxypyrrolidine-2-carboxylate 
• 912289-32-8 N-[2-nitro-4,5-dimethoxybenzoyl]-L-hydroxyproline ethyl ester 
• 107746-25-8 (2S,4R)-1-benzyl-4-hydroxy-2-hydroxymethylpyrrolidine 
• 142292-37-3 (2S,4S)-(4-amino-1-benzylpyrrolidin-2-yl)methanol 
• 627100-82-7 (2S,4R)-(4-aminomethyl-1-benzylpyrrolidin-2-yl)methanol 
• 627100-80-5 ethyl (2S,4S)-1-benzyl-4-cyanoprolinate 
• 627100-81-6 ethyl (2S,4S)-4-azido-1-benzylprolinate 
• 154343-00-7 (3R,5S)-1-benzyl-5-(tert-butyldimethylsilyloxymethyl)pyrrolidin-3-ol 
• 627100-77-0 (3R,5S)-1-benzyl-5-(tert-butyldimethylsilyloxymethyl)pyrrolidin-3-yl methanesulfonate 
• 627100-71-4 ethyl (2S,4R)-1-benzyl-4-(4-methylphenylsulfonyloxy)prolinate 

Relevant articles and documents

Amino 6-membered ring derivative and pharmaceutical applications thereof including the use for manufacturing dipeptidyl peptidase-4(IDPP-IV) inhibitor

The present invention relates to an amino 6-membered ring derivative and pharmaceutical applications thereof, which specifically relates to the amino 6-membered ring derivative represented by the general formula (I) or stereoisomers thereof, pharmaceutically acceptable salts thereof, a prodrug, a pharmaceutical composition comprising the derivative, and the pharmaceutical use for manufacturing dipeptidyl peptidase-4(IDPP-IV) inhibitor, wherein the definition of each substituent in the general formula (I) is the same as described in the specification.

A formal synthesis of (+)-lactacystin from 4-hydroxyproline

A formal synthesis of (+)-lactacystin has been completed from trans-4-hydroxyproline, using a diastereoselective enolate acylation reaction as a key step. Diastereoselectivity was seen to vary as a function of the steric bulk of the C4-O-protecting group, and contrary to expectations, the best diastereoselectivities were obtained when the small methyl carbonate protecting group was used. The formal synthesis was then completed by intercepting Shibasaki's route via methyl carbonate deprotection, dehydration, 3-pyrroline to 3-pyrrolinone oxidation, hydrogenation and N-CO2Me deprotection.

HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE

The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.